Interestingly, EGFR-TKI-resistant cells had drastically reduced cell survival and migration after treatment with the SFK inhibitor dasatinib, demonstrating that Src inhibitors may overcome EGFR inhibitor resistance in lung cancer cells [89]. Here, SRC is linked to lung carcinoma.